{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:06:05Z","timestamp":1790683565478,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12012-025-09994-2","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:27:10Z","timestamp":1746509230000},"page":"979-993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TXB-001, A Newly-Developed Polymer-Conjugated Anthracycline, Alleviates Anthracycline-Induced Cardiotoxicity"],"prefix":"10.1007","volume":"25","author":[{"given":"Miki","family":"Nonaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikito","family":"Hirakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuka","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Tomikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Shimozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Narumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiyu","family":"Oshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Uezono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"9994_CR1","doi-asserted-by":"publisher","unstructured":"(2019). Study cancer survivors. Nature, 568(7751), 143. https:\/\/doi.org\/10.1038\/d41586-019-01095-9","DOI":"10.1038\/d41586-019-01095-9"},{"issue":"12","key":"9994_CR2","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1021\/acs.molpharmaceut.6b00697","volume":"13","author":"H Nakamura","year":"2016","unstructured":"Nakamura, H., Koziolov\u00e1, E., Chytil, P., Tsukigawa, K., Fang, J., Haratake, M., & Maeda, H. (2016). Pronounced cellular uptake of pirarubicin versus that of other anthracyclines: Comparison of HPMA copolymer conjugates of pirarubicin and doxorubicin. Molecular Pharmaceutics, 13(12), 4106\u20134115. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00697","journal-title":"Molecular Pharmaceutics"},{"key":"9994_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O\u2019Brien, M. E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., Orlandi, F., Mellars, L., Alland, L., & Tendler, C. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of oncology\u202f: Official journal of the European Society for Medical Oncology, 15, 440\u2013449. https:\/\/doi.org\/10.1093\/annonc\/mdh097","journal-title":"Annals of oncology : Official journal of the European Society for Medical Oncology"},{"key":"9994_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fphar.2014.00077","volume":"5","author":"AM Jhaveri","year":"2014","unstructured":"Jhaveri, A. M., & Torchilin, V. P. (2014). Multifunctional polymeric micelles for delivery of drugs and siRNA. Frontiers in Pharmacology, 5, 77. https:\/\/doi.org\/10.3389\/fphar.2014.00077","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"9994_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/micc.12228","volume":"23","author":"H Maeda","year":"2016","unstructured":"Maeda, H., Tsukigawa, K., & Fang, J. (2016). A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: Next-generation chemotherapeutics and photodynamic therapy-problems, solutions, and prospects. Microcirculation, 23(3), 173\u2013182. https:\/\/doi.org\/10.1111\/micc.12228","journal-title":"Microcirculation"},{"key":"9994_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11030229","author":"H Maeda","year":"2021","unstructured":"Maeda, H. (2021). The 35th anniversary of the discovery of EPR effect: A new wave of nanomedicines for tumor-targeted drug delivery-personal remarks and future prospects. Journal of Personalized Medicine. https:\/\/doi.org\/10.3390\/jpm11030229","journal-title":"Journal of Personalized Medicine"},{"issue":"12 Pt 1","key":"9994_CR7","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research, 46(12 Pt 1), 6387\u20136392.","journal-title":"Cancer Research"},{"issue":"4","key":"9994_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccl.2019.07.005","volume":"37","author":"R Barish","year":"2019","unstructured":"Barish, R., Gates, E., & Barac, A. (2019). Trastuzumab-induced cardiomyopathy. Cardiology Clinics, 37(4), 407\u2013418. https:\/\/doi.org\/10.1016\/j.ccl.2019.07.005","journal-title":"Cardiology Clinics"},{"issue":"8","key":"9994_CR9","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/s1470-2045(17)30535-1","volume":"18","author":"BE Levis","year":"2017","unstructured":"Levis, B. E., Binkley, P. F., & Shapiro, C. L. (2017). Cardiotoxic effects of anthracycline-based therapy: What is the evidence and what are the potential harms? The lancet Oncology, 18(8), e445\u2013e456. https:\/\/doi.org\/10.1016\/s1470-2045(17)30535-1","journal-title":"The lancet Oncology"},{"issue":"24","key":"9994_CR10","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ET Yeh","year":"2009","unstructured":"Yeh, E. T., & Bickford, C. L. (2009). Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. Journal of the American College of Cardiology, 53(24), 2231\u20132247. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.050","journal-title":"Journal of the American College of Cardiology"},{"issue":"36","key":"9994_CR11","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano, J. L., Lancellotti, P., Rodriguez Mu\u00f1oz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., & Suter, T. M. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal, 37(36), 2768\u20132801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","journal-title":"European Heart Journal"},{"issue":"18","key":"9994_CR12","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., Becker, J. R., Slosky, D. A., Phillips, E. J., Pilkinton, M. A., Craig-Owens, L., Kola, N., Plautz, G., Reshef, D. S., Deutsch, J. S., \u2026 Moslehi, J. J. (2016). Fulminant myocarditis with combination immune checkpoint blockade. New England Journal of Medicine, 375(18), 1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"9994_CR13","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/s1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018). Immune checkpoint inhibitors and cardiovascular toxicity. The lancet Oncology, 19(9), e447\u2013e458. https:\/\/doi.org\/10.1016\/s1470-2045(18)30457-1","journal-title":"The lancet Oncology"},{"issue":"15","key":"9994_CR14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi, J. J. (2016). Cardiovascular toxic effects of targeted cancer therapies. New England Journal of Medicine, 375(15), 1457\u20131467. https:\/\/doi.org\/10.1056\/NEJMra1100265","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"9994_CR15","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00280-015-2875-8","volume":"76","author":"Z Ajgal","year":"2015","unstructured":"Ajgal, Z., Chapuis, N., Emile, G., Cessot, A., Tigaud, J. M., Huillard, O., Boudou-Rouquette, P., Fontenay, M., Goldwasser, F., & Alexandre, J. (2015). Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: Assessment of monocyte count and baseline clinical parameters. Cancer Chemotherapy and Pharmacology, 76(5), 1033\u20131039. https:\/\/doi.org\/10.1007\/s00280-015-2875-8","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"1","key":"9994_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","volume":"26","author":"N Yokomichi","year":"2013","unstructured":"Yokomichi, N., Nagasawa, T., Coler-Reilly, A., Suzuki, H., Kubota, Y., Yoshioka, R., Tozawa, A., Suzuki, N., & Yamaguchi, Y. (2013). Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin. Human Cell, 26(1), 8\u201318. https:\/\/doi.org\/10.1007\/s13577-012-0057-0","journal-title":"Human Cell"},{"key":"9994_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jconrel.2013.11.011","volume":"174","author":"H Nakamura","year":"2014","unstructured":"Nakamura, H., Etrych, T., Chytil, P., Ohkubo, M., Fang, J., Ulbrich, K., & Maeda, H. (2014). Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. Journal of Controlled Release, 174, 81\u201387. https:\/\/doi.org\/10.1016\/j.jconrel.2013.11.011","journal-title":"Journal of Controlled Release"},{"key":"9994_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153698","author":"A Makimoto","year":"2021","unstructured":"Makimoto, A., Fang, J., & Maeda, H. (2021). Development of a selective tumor-targeted drug delivery system: hydroxypropyl-acrylamide polymer-conjugated pirarubicin (P-THP) for pediatric solid tumors. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13153698","journal-title":"Cancers (Basel)"},{"key":"9994_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2024.116912","volume":"485","author":"M Hirakata","year":"2024","unstructured":"Hirakata, M., Tomikawa, E., Sakai, C., Uchida, M., Okano, T., Shimozono, R., Kawai, M., Itaba, S., Munakata, L., Suzuki, R., & Oshida, K. (2024). TXB-001, a newly-developed polymer-conjugated anthracycline: Significantly lower adverse effects in animal models of alopecia and hand-foot syndrome. Toxicology and Applied Pharmacology, 485, 116912. https:\/\/doi.org\/10.1016\/j.taap.2024.116912","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"2","key":"9994_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/circresaha.106.146670","volume":"101","author":"CK Du","year":"2007","unstructured":"Du, C. K., Morimoto, S., Nishii, K., Minakami, R., Ohta, M., Tadano, N., Lu, Q. W., Wang, Y. Y., Zhan, D. Y., Mochizuki, M., Kita, S., Miwa, Y., Takahashi-Yanaga, F., Iwamoto, T., Ohtsuki, I., & Sasaguri, T. (2007). Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circulation Research, 101(2), 185\u2013194. https:\/\/doi.org\/10.1161\/circresaha.106.146670","journal-title":"Circulation Research"},{"issue":"9","key":"9994_CR21","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1111\/bph.13062","volume":"172","author":"M Nonaka","year":"2015","unstructured":"Nonaka, M., Morimoto, S., Murayama, T., Kurebayashi, N., Li, L., Wang, Y. Y., Arioka, M., Yoshihara, T., Takahashi-Yanaga, F., & Sasaguri, T. (2015). Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. British Journal of Pharmacology, 172(9), 2369\u20132382. https:\/\/doi.org\/10.1111\/bph.13062","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"9994_CR22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1161\/01.res.86.4.386","volume":"86","author":"S Miyata","year":"2000","unstructured":"Miyata, S., Minobe, W., Bristow, M. R., & Leinwand, L. A. (2000). Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circulation Research, 86(4), 386\u2013390. https:\/\/doi.org\/10.1161\/01.res.86.4.386","journal-title":"Circulation Research"},{"issue":"6","key":"9994_CR23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00210-023-02382-z","volume":"396","author":"PL Dulf","year":"2023","unstructured":"Dulf, P. L., Mocan, M., Coad\u0103, C. A., Dulf, D. V., Moldovan, R., Baldea, I., Farcas, A. D., Blendea, D., & Filip, A. G. (2023). Doxorubicin-induced acute cardiotoxicity is associated with increased oxidative stress, autophagy, and inflammation in a murine model. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology, 396(6), 1105\u20131115. https:\/\/doi.org\/10.1007\/s00210-023-02382-z","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"issue":"1","key":"9994_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1074248408329449","volume":"14","author":"DS Hydock","year":"2009","unstructured":"Hydock, D. S., Lien, C. Y., & Hayward, R. (2009). Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. Journal of Cardiovascular Pharmacology and Therapeutics, 14(1), 59\u201367. https:\/\/doi.org\/10.1177\/1074248408329449","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"4","key":"9994_CR25","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1472-8206.2012.01037.x","volume":"27","author":"S Kharin","year":"2013","unstructured":"Kharin, S., Krandycheva, V., Tsvetkova, A., Strelkova, M., & Shmakov, D. (2013). Remodeling of ventricular repolarization in a chronic doxorubicin cardiotoxicity rat model. Fundamental & Clinical Pharmacology, 27(4), 364\u2013372. https:\/\/doi.org\/10.1111\/j.1472-8206.2012.01037.x","journal-title":"Fundamental & Clinical Pharmacology"},{"issue":"1","key":"9994_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0008-6363(95)00121-2","volume":"31","author":"AJ de Bold","year":"1996","unstructured":"de Bold, A. J., Bruneau, B. G., & Kuroski de Bold, M. L. (1996). Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovascular Research, 31(1), 7\u201318. https:\/\/doi.org\/10.1016\/S0008-6363(95)00121-2","journal-title":"Cardiovascular Research"},{"issue":"11","key":"9994_CR27","first-page":"4401","volume":"29","author":"DS Hydock","year":"2009","unstructured":"Hydock, D. S., Wonders, K. Y., Schneider, C. M., & Hayward, R. (2009). Voluntary wheel running in rats receiving doxorubicin: Effects on running activity and cardiac myosin heavy chain. Anticancer Research, 29(11), 4401\u20134407.","journal-title":"Anticancer Research"},{"issue":"1","key":"9994_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1186\/s12967-023-04715-1","volume":"21","author":"P Tai","year":"2023","unstructured":"Tai, P., Chen, X., Jia, G., Chen, G., Gong, L., Cheng, Y., Li, Z., Wang, H., Chen, A., Zhang, G., Zhu, Y., Xiao, M., Wang, Z., Liu, Y., Shan, D., He, D., Li, M., Zhan, T., Khan, A., \u2026 Cao, K. (2023). WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis. Journal of Translational Medicine, 21(1), 823. https:\/\/doi.org\/10.1186\/s12967-023-04715-1","journal-title":"Journal of Translational Medicine"},{"issue":"8","key":"9994_CR29","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1161\/circresaha.113.302187","volume":"113","author":"D Eisner","year":"2013","unstructured":"Eisner, D., Caldwell, J., & Trafford, A. (2013). Sarcoplasmic reticulum Ca-ATPase and heart failure 20 years later. Circulation Research, 113(8), 958\u2013961. https:\/\/doi.org\/10.1161\/circresaha.113.302187","journal-title":"Circulation Research"},{"key":"9994_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.yjmcc.2018.11.019","volume":"126","author":"A Llach","year":"2019","unstructured":"Llach, A., Mazevet, M., Mateo, P., Villejouvert, O., Ridoux, A., Rucker-Martin, C., Ribeiro, M., Fischmeister, R., Crozatier, B., Benitah, J. P., Morel, E., & G\u00f3mez, A. M. (2019). Progression of excitation-contraction coupling defects in doxorubicin cardiotoxicity. Journal of Molecular and Cellular Cardiology, 126, 129\u2013139. https:\/\/doi.org\/10.1016\/j.yjmcc.2018.11.019","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"11","key":"9994_CR31","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.jacc.2004.08.057","volume":"44","author":"T Takaseya","year":"2004","unstructured":"Takaseya, T., Ishimatsu, M., Tayama, E., Nishi, A., Akasu, T., & Aoyagi, S. (2004). Mechanical unloading improves intracellular Ca2+ regulation in rats with doxorubicin-induced cardiomyopathy. Journal of the American College of Cardiology, 44(11), 2239\u20132246. https:\/\/doi.org\/10.1016\/j.jacc.2004.08.057","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"9994_CR32","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s12013-014-0130-2","volume":"70","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y., Chen, Y., Zhang, M., Tang, Y., Xie, Y., Huang, X., & Li, Y. (2014). Doxorubicin induces sarcoplasmic reticulum calcium regulation dysfunction via the decrease of SERCA2 and phospholamban expressions in rats. Cell Biochemistry and Biophysics, 70(3), 1791\u20131798. https:\/\/doi.org\/10.1007\/s12013-014-0130-2","journal-title":"Cell Biochemistry and Biophysics"},{"issue":"3","key":"9994_CR33","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1124\/jpet.103.053413","volume":"306","author":"GJ Charrois","year":"2003","unstructured":"Charrois, G. J., & Allen, T. M. (2003). Multiple injections of pegylated liposomal Doxorubicin: Pharmacokinetics and therapeutic activity. Journal of Pharmacology and Experimental Therapeutics, 306(3), 1058\u20131067. https:\/\/doi.org\/10.1124\/jpet.103.053413","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"9994_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2019.120358","volume":"208","author":"H Wang","year":"2020","unstructured":"Wang, H., Zheng, M., Gao, J., Wang, J., Zhang, Q., Fawcett, J. P., He, Y., & Gu, J. (2020). Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice. Talanta, 208, 120358. https:\/\/doi.org\/10.1016\/j.talanta.2019.120358","journal-title":"Talanta"},{"issue":"4","key":"9994_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/mpo.2950220410","volume":"22","author":"AA Miller","year":"1994","unstructured":"Miller, A. A., & Salewski, E. (1994). Prospects for pirarubicin. Medical and Pediatric Oncology, 22(4), 261\u2013268. https:\/\/doi.org\/10.1002\/mpo.2950220410","journal-title":"Medical and Pediatric Oncology"},{"issue":"10","key":"9994_CR36","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.7164\/antibiotics.32.1082","volume":"32","author":"H Umezawa","year":"1979","unstructured":"Umezawa, H., Takahashi, Y., Kinoshita, M., Naganawa, H., Masuda, T., Ishizuka, M., Tatsuta, K., & Takeuchi, T. (1979). Tetrahydropyranyl derivatives of daunomycin and adriamycin. The Journal of Antibiotics (Tokyo), 32(10), 1082\u20131084. https:\/\/doi.org\/10.7164\/antibiotics.32.1082","journal-title":"The Journal of Antibiotics (Tokyo)"},{"key":"9994_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/472565","author":"RC Chen","year":"2015","unstructured":"Chen, R. C., Xu, X. D., Zhi Liu, X., Sun, G. B., Zhu, Y. D., Dong, X., Wang, J., Zhang, H. J., Zhang, Q., & Sun, X. B. (2015). Total flavonoids from clinopodium Chinense (Benth.) O. Ktze protect against doxorubicin-induced cardiotoxicity In Vitro and In Vivo. Evid Based Complementary Alternative Medicine. https:\/\/doi.org\/10.1155\/2015\/472565","journal-title":"Evid Based Complementary Alternative Medicine"},{"issue":"12","key":"9994_CR38","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/jpp\/rgac063","volume":"74","author":"IC Jones","year":"2022","unstructured":"Jones, I. C., & Dass, C. R. (2022). Doxorubicin-induced cardiotoxicity: Causative factors and possible interventions. Journal of Pharmacy and Pharmacology, 74(12), 1677\u20131688. https:\/\/doi.org\/10.1093\/jpp\/rgac063","journal-title":"Journal of Pharmacy and Pharmacology"},{"issue":"12","key":"9994_CR39","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/jco.2005.12.121","volume":"23","author":"SE Lipshultz","year":"2005","unstructured":"Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005). Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 23(12), 2629\u20132636. https:\/\/doi.org\/10.1200\/jco.2005.12.121","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"9994_CR40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1142\/s0192415x19500551","volume":"47","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y., Ma, X. Y., Zhang, T., Qin, M., Sun, B., Li, Q., Hu, D. W., & Ren, L. Q. (2019). Protective effects of apocynum venetum against pirarubicin-induced cardiotoxicity. American Journal of Chinese Medicine, 47(5), 1075\u20131097. https:\/\/doi.org\/10.1142\/s0192415x19500551","journal-title":"American Journal of Chinese Medicine"},{"issue":"5","key":"9994_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1600-0609.1999.tb01137.x","volume":"63","author":"N Niitsu","year":"1999","unstructured":"Niitsu, N., & Umeda, M. (1999). Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin\u2019s lymphoma: Comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. European Journal of Haematology, 63(5), 337\u2013344. https:\/\/doi.org\/10.1111\/j.1600-0609.1999.tb01137.x","journal-title":"European Journal of Haematology"},{"issue":"11","key":"9994_CR42","first-page":"3645","volume":"5","author":"RL Hong","year":"1999","unstructured":"Hong, R. L., Huang, C. J., Tseng, Y. L., Pang, V. F., Chen, S. T., Liu, J. J., & Chang, F. H. (1999). Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? Clinical Cancer Research, 5(11), 3645\u20133652.","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"9994_CR43","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.nano.2017.02.008","volume":"13","author":"CM Dawidczyk","year":"2017","unstructured":"Dawidczyk, C. M., Russell, L. M., Hultz, M., & Searson, P. C. (2017). Tumor accumulation of liposomal doxorubicin in three murine models: Optimizing delivery efficiency. Nanomedicine, 13(5), 1637\u20131644. https:\/\/doi.org\/10.1016\/j.nano.2017.02.008","journal-title":"Nanomedicine"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-09994-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-025-09994-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-09994-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:15:20Z","timestamp":1749654920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-025-09994-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["9994"],"URL":"https:\/\/doi.org\/10.1007\/s12012-025-09994-2","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded in part by Toray Industries, Inc., to which the following authors belong: M Hirakata, C Sakai, E Tomikawa, A Izawa, T Nishi, Y Koga, K Takahashi, R Shimozono, T Miyoshi, K Oshida, and M Uchida. There is no other conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}